Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zur Bewertung der Wirksamkeit und Sicherheit von JNJ-77242113 im Vergleich zu Placebo und Ustekinumab bei Teilnehmern mit mittelschwerer bis schwerer Plaque-Psoriasis (ICONIC-ASCEND)

2. November 2026 aktualisiert von: Janssen Research & Development, LLC

Ein multizentrisches, randomisiertes, doppelblindes, placebokontrolliertes und ustekinumab aktiver Kompontroll-Studien zur Bewertung der Wirksamkeit und Sicherheit von JNJ-77242113 zur Behandlung von Teilnehmern mit mittelschwerer bis schwerer Plakique Psoriasis

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Tatsächlich)

752

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Barrio Gral Paz Cba Capital, Argentinien, X5000
        • Consultora Integral de Salud SRL
      • Buenos Aires, Argentinien, B1643CRO
        • Instituto Medico De Alta Complejidad (IMAC)
      • Buenos Aires, Argentinien, C1417EYG
        • Mindout Research
      • Buenos Aires, Argentinien, C1425
        • Instituto de Neumonologia y Dermatologia
      • CABA, Argentinien, C1061AAS
        • CIPREC
      • CABA, Argentinien, C1199ABB
        • Hospital Italiano de Buenos Aires
      • CABA, Argentinien, C1055AAO
        • Buenos Aires Skin
      • CABA, Argentinien, C1056ABH
        • Investigaciones Medicas IMOBA SRL
      • CABA, Argentinien, C1128
        • Mautalen Salud e Investigacion
      • Caba, Argentinien, C1122AAF
        • Halitus Instituto Medico S.A. - Dermatologia y Estetica
      • Rosario, Argentinien, S2000DBS
        • Instituto De Especialidades De La Salud SRL
      • San Fernando, Argentinien, B1646
        • MR Medicina Reumatologica
      • San Miguel de Tucumán, Argentinien, T4000
        • Instituto de Investigaciones Medicas Tucuman
      • Clayton, Australien, 3168
        • Monash Medical Centre
      • Coorparoo, Australien, 4151
        • Cornerstone Dermatology
      • Greenslopes, Australien, 4120
        • Veracity Clinical Research
      • Kogarah, Australien, 2217
        • Premier Specialists
      • Melbourne, Australien, 3004
        • The Alfred Hospital
      • Melbourne, Australien, 3050
        • Royal Melbourne Hospital
      • Mitcham, Australien, 3132
        • ISHI dermatology
      • Westmead, Australien, 2145
        • Westmead Hospital
      • Brussels, Belgien, 1090
        • UZ Brussel
      • Ghent, Belgien, 9000
        • Ghent University Hospital
      • Ghent, Belgien, 9000
        • AZ St. Lucas
      • Leuven, Belgien, 3000
        • Universitair Ziekenhuis Leuven
      • Liège, Belgien, 4000
        • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
      • Maldegem, Belgien, 9990
        • Dermatologie Maldegem
      • Augsburg, Deutschland, 86179
        • Klinikum Augsburg
      • Bad Bentheim, Deutschland, 48455
        • Fachklinik Bad Bentheim
      • Berlin, Deutschland, 10789
        • ISA - Interdisciplinary Study Association GmbH
      • Bonn, Deutschland, 53127
        • Universitatsklinikum Bonn
      • Bramsche, Deutschland, 49565
        • Studienzentrum an der Hase GbR
      • Darmstadt, Deutschland, 64283
        • Rosenpark Research GmbH
      • Dresden, Deutschland, 01307
        • Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
      • Friedrichshafen, Deutschland, 88045
        • Derma-Study-Center Friedrichshafen GmbH
      • Kiel, Deutschland, 24105
        • Universitaetsklinikum Schleswig Holstein Campus Kiel
      • Langenau, Deutschland, 89129
        • Studienzentrum Dr Schwarz Germany
      • Mahlow, Deutschland, 15831
        • Dermatologie Mahlow
      • Mainz, Deutschland, 55128
        • Gemeinschaftspraxis Dres. Quist
      • Münster, Deutschland, 48149
        • Universitaetsklinikum Muenster
      • Witten, Deutschland, 58453
        • Hautarztpraxis
      • Aalborg, Dänemark, 9100
        • Aalborg Sygehus Syd
      • Aarhus, Dänemark, 8200
        • Aarhus University Hospital
      • Hellerup, Dänemark, 2900
        • Gentofte Hospital
      • København NV, Dänemark, 2400
        • Bispebjerg Hospital
      • Odense, Dänemark, 5000
        • Odense University Hospital
      • Roskilde, Dänemark, 4000
        • Sjællands University hospital
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Kanada, A1E 1V4
        • Skincare Studio Inc Dermatology Clinical Trials
    • Ontario
      • Ajax, Ontario, Kanada, L1S7K8
        • CCA Medical Research Corporation
      • Barrie, Ontario, Kanada, L4M 7G1
        • SimcoDerm Medical and Surgical Dermatology Centre
      • Hamilton, Ontario, Kanada, L8N 1Y2
        • Dermatrials Research
      • London, Ontario, Kanada, N6A 5R9
        • Lovegrove Dermatology
      • Markham, Ontario, Kanada, L3P 1X3
        • Lynderm Research Inc.
      • Waterloo, Ontario, Kanada, N2J 1C4
        • Alliance Clinical Trials
    • Quebec
      • Montreal, Quebec, Kanada, H2X 2V1
        • Innovaderm Research Inc.
      • Québec, Quebec, Kanada, G1W 4R4
        • The Centre de recherche Saint-Louis
      • Bialystok, Polen, 15 375
        • Specderm Poznanska sp j
      • Bialystok, Polen, 15-351
        • Osteo-Medic s.c A. Racewicz, J Supronik
      • Elblag, Polen, 82 300
        • Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
      • Katowice, Polen, 40 568
        • Care Clinic Sp z o o
      • Krakow, Polen, 30 002
        • Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
      • Lodz, Polen, 90-265
        • Dermed Centrum Medyczne Sp z o o
      • Olsztyn, Polen, 10-117
        • Etyka Osrodek Badan Klinicznych
      • Poznan, Polen, 60 529
        • SOLUMED Centrum Medyczne
      • Skierniewice, Polen, 96 100
        • Velocity Nova Sp z o o
      • Warsaw, Polen, 02 661
        • Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
      • Warsaw, Polen, 02 953
        • Klinika Ambroziak Dermatologia
      • Wroclaw, Polen, 52 416
        • Centrum Medyczne Oporow
      • Wroclaw, Polen, 51 685
        • WroMedica I Bielicka A Strzalkowska s c
      • Guimarães, Portugal, 4835 044
        • Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
      • Leiria, Portugal, 2410 197
        • Unidade Local De Saude Da Regiao De Leiria Epe
      • Lisbon, Portugal, 1169 050
        • Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
      • Lisbon, Portugal, 1998 018
        • Hosp. Cuf Descobertas
      • Porto, Portugal, 4099 001
        • Ulssa Hosp. Santo Antonio
      • Alicante, Spanien, 03010
        • Hosp. Gral. Univ. Dr. Balmis
      • Barakaldo, Spanien, 48902
        • Hosp. Univ. de Cruces
      • Barcelona, Spanien, 08036
        • Hosp. Clinic de Barcelona
      • Granada, Spanien, 18016
        • Hosp. Univ. San Cecilio
      • Madrid, Spanien, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Spanien, 28006
        • Hosp. Univ. de La Princesa
      • Madrid, Spanien, 28002
        • Grupo Dermatologico Y Estetico Pedro Jaen
      • Manises, Spanien, 46940
        • Hosp. de Manises
      • Santiago Compostela, Spanien, 15706
        • Hosp. Clinico Univ. de Santiago
      • Seville, Spanien, 41009
        • Hosp. Virgen Macarena
      • Seville, Spanien, 41014
        • Hosp. Ntra. Sra. de Valme
      • Valencia, Spanien, 46026
        • Hosp. Univ. I Politecni La Fe
      • Villajoyosa, Spanien, 03570
        • Hosp. de La Marina Baixa
      • Zaragoza, Spanien, 50009
        • Hosp. Clinico Univ. Lozano Blesa
      • Zaragoza, Spanien, 50009
        • Hosp. Univ. Miguel Servet
      • Budapest, Ungarn, 1036
        • Obudai Egeszsegugyi Centrum Kft
      • Budapest, Ungarn, 1152
        • Uno Medical Trials Ltd.
      • Debrecen, Ungarn, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Debrecen, Ungarn, 4031
        • Derma-B Kft
      • Gyula, Ungarn, 5700
        • Synexus Magyarorszag Kft
      • Gyöngyös, Ungarn, 3200
        • Gyongyosi Bugat Pal Korhaz
      • Hódmezővásárhely, Ungarn, 6800
        • Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
      • Kaposvár, Ungarn, 7400
        • Somogy Varmegyei Kaposi Mor Oktato Korhaz
      • Kecskemét, Ungarn, 6000
        • Bacs-kiskun Megyei Korhaz
      • Szolnok, Ungarn, 5000
        • Allergo-Derm Bakos Kft.
      • Veszprém, Ungarn, 8200
        • Medmare Egeszsegugyi Es Szolgaltato Bt.
    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35244
        • Cahaba Research Inc
    • California
      • Encinitas, California, Vereinigte Staaten, 92024
        • California Dermatology & Clinical Research Institute
      • Encino, California, Vereinigte Staaten, 91436
        • T Joseph Raoof Md Inc
      • Fountain Valley, California, Vereinigte Staaten, 92708
        • First OC Dermatology
      • Oceanside, California, Vereinigte Staaten, 92056
        • Dermatologist Medical Group of North County, Inc.
      • Rocklin, California, Vereinigte Staaten, 95765
        • NorCal Clinical Research
      • Sacramento, California, Vereinigte Staaten, 95815
        • Integrative Skin Science and Research
      • San Diego, California, Vereinigte Staaten, 92103
        • MedDerm Associates
      • Santa Ana, California, Vereinigte Staaten, 92701
        • Southern California Dermatology
      • Sylmar, California, Vereinigte Staaten, 91342
        • Olive View-UCLA Education & Research Institute
    • Connecticut
      • Farmington, Connecticut, Vereinigte Staaten, 06030
        • University of Conn Health Center
    • Florida
      • Miami, Florida, Vereinigte Staaten, 33155
        • Bioclinical Research Alliance Inc.
      • Miami, Florida, Vereinigte Staaten, 33126
        • Driven Research LLC
      • Ocala, Florida, Vereinigte Staaten, 34470
        • Renstar Medical Research
      • Tampa, Florida, Vereinigte Staaten, 33613
        • Forcare Clinical Research Inc
    • Georgia
      • Alpharetta, Georgia, Vereinigte Staaten, 30022
        • Hamilton Research LLC
    • Illinois
      • Skokie, Illinois, Vereinigte Staaten, 60076
        • Northshore Medical Group
    • Indiana
      • Plainfield, Indiana, Vereinigte Staaten, 46168
        • Indiana Clinical Trial Center
    • Iowa
      • Iowa City, Iowa, Vereinigte Staaten, 52242
        • University of Iowa
    • Kentucky
      • Bowling Green, Kentucky, Vereinigte Staaten, 42104
        • Equity Medical
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02111
        • Tufts Medical Center
      • Brighton, Massachusetts, Vereinigte Staaten, 02135
        • Metro Boston Clinical Partners
    • Michigan
      • Caledonia, Michigan, Vereinigte Staaten, 49316
        • The Derm Institute of West Michigan
      • Detroit, Michigan, Vereinigte Staaten, 48202
        • Henry Ford Hospital
      • Fort Gratiot, Michigan, Vereinigte Staaten, 48059
        • Hamzavi Dermatology
      • Troy, Michigan, Vereinigte Staaten, 48084
        • Somerset Skin Centre
    • Minnesota
      • New Brighton, Minnesota, Vereinigte Staaten, 55112
        • Minnesota Clinical Study Center
    • Missouri
      • Kirksville, Missouri, Vereinigte Staaten, 63501
        • Cleaver Dermatology
      • Saint Joseph, Missouri, Vereinigte Staaten, 64506
        • MediSearch Clinical Trials
    • New York
      • New York, New York, Vereinigte Staaten, 10075
        • Sadick Research Group
      • New York, New York, Vereinigte Staaten, 10028
        • Mount Sinai Doctors Dermatology
    • North Carolina
      • Wilmington, North Carolina, Vereinigte Staaten, 28405
        • Wilmington Dermatology Center
    • Ohio
      • Boardman, Ohio, Vereinigte Staaten, 44512
        • Optima Research
      • Mayfield Heights, Ohio, Vereinigte Staaten, 44124
        • Apex Dermatology Mayfield Heights
    • Oregon
      • Portland, Oregon, Vereinigte Staaten, 97210
        • Oregon Dermatology and Research Center
      • Portland, Oregon, Vereinigte Staaten, 97201
        • Oregon Medical Research Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19114
        • Clinical Research Philadelphia
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
        • UPMC Department of Dermatology
    • South Dakota
      • Rapid City, South Dakota, Vereinigte Staaten, 57702
        • Health Concepts
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37211
        • Advanced Research Experts PLLC
    • Texas
      • Arlington, Texas, Vereinigte Staaten, 76011
        • Arlington Research Center, Inc.
      • Dallas, Texas, Vereinigte Staaten, 75231
        • Modern Research Associates PLLC
      • Houston, Texas, Vereinigte Staaten, 77004
        • Center for Clinical Studies 1
      • San Antonio, Texas, Vereinigte Staaten, 78218
        • Texas Dermatology and Laser Specialists
      • San Antonio, Texas, Vereinigte Staaten, 78213
        • Progressive Clinical Research
      • Webster, Texas, Vereinigte Staaten, 77598
        • Center for Clinical Studies
    • Utah
      • West Valley City, Utah, Vereinigte Staaten, 84120
        • Kalo Clinical Research
    • Washington
      • Mill Creek, Washington, Vereinigte Staaten, 98012
        • Frontier Derm Partners CRO, LLC
      • Dudley, Vereinigtes Königreich, DY1 2HQ
        • Dudley Group NHS Foundation Trust
      • Harrow, Vereinigtes Königreich, HA1 3UJ
        • London North West University Healthcare NHS Trust
      • Kings Lynn, Vereinigtes Königreich, PE30 4ET
        • The Queen Elizabeth Hospital NHS Foundation Trust
      • London, Vereinigtes Königreich, SE1 9RT
        • Guys and St Thomas NHS Foundation Trust
      • Reading, Vereinigtes Königreich, RG1 5AN
        • Royal Berkshire Hospital
      • Salford, Vereinigtes Königreich, M6 8HD
        • Salford Royal Hospital
      • Southampton, Vereinigtes Königreich, So166yd
        • University Hospital Southampton
      • Wakefield, Vereinigtes Königreich, WF1 4DG
        • Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital
      • Feldkirch, Österreich, 6800
        • LKH Feldkirch
      • Linz, Österreich, 4020
        • Kepler Universitatsklinikum GmbH
      • Sankt Pölten, Österreich, 3100
        • Universtitatsklinikum St Poelten
      • Vienna, Österreich, 1090
        • Allgemeines Krankenhaus der Stadt Wien

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

12 Jahre und älter (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
  • Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
  • Total psoriasis area and severity index (PASI) >=12 at screening and baseline
  • Total investigator global assessment (IGA) >=3 at screening and baseline
  • Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

  • Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
  • Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
  • Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
  • Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Arm 1: JNJ 77242113

Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind.

JNJ-77242113 will be administered orally.

Matching placebo will be administered subcutaneously.

Placebo-Komparator: Arm 2: Placebo

Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104.

JNJ-77242113 will be administered orally.

Matching placebo will be administered subcutaneously.

Matching placebo will be administered orally.

Aktiver Komparator: Arm 3: Ustekinumab

Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28.

JNJ-77242113 will be administered orally.

Matching placebo will be administered orally.

Ustekinumab will be administered subcutaneously.

Andere Namen:
  • STELARA
  • CNTO 1275

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
Zeitfenster: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Zeitfenster: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 16

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
Zeitfenster: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Zeitfenster: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
Zeitfenster: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
Zeitfenster: Week 28

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
Zeitfenster: Week 28

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
Zeitfenster: Week 28

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 28
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
Zeitfenster: Week 16

PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
Zeitfenster: Week 16

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 16
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: Up to Week 108

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product & is medically important.

Up to Week 108
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
Zeitfenster: Week 16

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease.

Week 16
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
Zeitfenster: Baseline up to Week 16

DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Baseline up to Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
Zeitfenster: Week 16

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Week 16
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
Zeitfenster: Baseline up to Week 16

BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.

Baseline up to Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
Zeitfenster: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
Zeitfenster: Baseline up to Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
Zeitfenster: Baseline up to Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
Zeitfenster: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
Zeitfenster: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
Zeitfenster: Baseline up to Week 28

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
Zeitfenster: Week 28

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
Zeitfenster: Baseline up to Week 16

BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.

Baseline up to Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
Zeitfenster: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
Zeitfenster: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Zeitfenster: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 16

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

15. April 2025

Primärer Abschluss (Tatsächlich)

17. November 2025

Studienabschluss (Geschätzt)

20. August 2027

Studienanmeldedaten

Zuerst eingereicht

11. April 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. April 2025

Zuerst gepostet (Tatsächlich)

18. April 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 77242113PSO3006
  • 77242113PSO3006 (Andere Kennung: Janssen Research & Development, LLC)
  • 2024-515706-77-00 (Registrierungskennung: EUCT number)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren